Abcuro Raises US$66M Series D to Fund a New Trial of Its Inclusion Body Myositis Drug
Abcuro, a clinical-stage biotechnology company based in Newton, Massachusetts, announced on Tuesday, August 18, 2026, the closing of a US$66 million Series D financing led by New Leaf Venture Partners, an existing investor. Rock Springs Capital is the only new name in the round. Returning backers include funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, and individual investors Nancy Chang and Shang Bay. Valuation and terms were not disclosed. The company is led by chief executive Alex Martin, with H. Jeffrey Wilkins as chief medical officer, George Eldridge as chief financial officer since August 2025, and Courtney Cupples as chief commercial officer since June 2025. Abcuro was founded in 2015; databases credit Stefano Gulla as founder.
The money funds a new, potentially registrational clinical study of ulviprubart (ABC008), a monoclonal antibody targeting killer cell lectin-like receptor G1, or KLRG1, in patients with less severe inclusion body myositis. Abcuro says it has been in discussions with the U.S. Food and Drug Administration, expects to start the study in the fourth quarter of 2026, and expects topline results in the second half of 2028; Martin told Endpoints News the company has alignment with the FDA on the path forward. The round follows a setback. Abcuro's Phase 2/3 MUSCLE study, which enrolled 272 patients, missed its primary endpoint — change in the IBM Functional Rating Scale at week 76 versus placebo — and its key secondary endpoints, results announced on February 24, 2026 and detailed at the 6th Global Conference on Myositis in Lisbon on March 26. In a pre-specified subgroup of patients whose baseline IBMFRS score was above 29, both dose groups declined 1.3 points over 76 weeks against 2.6 for placebo, a 50% slowing. Abcuro previously raised a US$200 million Series C led by NEA in February 2025 and a US$155 million Series B in 2023 co-led by Redmile Group and Bain Capital Life Sciences; cumulative funding before this round is reported as roughly US$415 million by CB Insights and US$452 million by Tracxn, a gap neither the company nor the databases explain.
Market Context
Inclusion body myositis has no approved pharmacologic treatment anywhere. It is a chronic, progressive autoimmune muscle disease that typically appears after age 50, in which cytotoxic T cells destroy muscle tissue and patients lose grip, dexterity and mobility. Abcuro estimates roughly 40,000 diagnosed patients in the United States and roughly 35,000 across major European countries and Japan, with less severe patients making up close to half of the total. Those figures sit well above earlier third-party counts: Fierce Biotech and others have described the population as about 50,000 across the U.S. and Europe combined, and the Muscular Dystrophy Association has been cited at roughly 20,000 in the U.S. The spread matters, because the commercial case rests on it. Ulviprubart is among the most advanced targeted candidates in a thin pipeline; prior attempts including arimoclomol and bimagrumab did not improve efficacy outcomes against placebo, and an academic Phase 3 of sirolimus has been running in parallel.
The financing environment rewards exactly this profile and punishes the opposite one. BioPharma Dive counted more than US$9.1 billion of biotech venture funding in the first half of 2026, the strongest first half since 2022, but about two-thirds of those rounds went to companies that already had a candidate in human testing, while J.P. Morgan tracked 50 seed and Series A deals worth US$2.3 billion in the first quarter, down from 60 deals worth US$3.7 billion a year earlier and on pace for the weakest year of first-time financings this decade. Autoimmune and cancer developers took more than 40% of first-half rounds. An insider-led round for a company with clinical data and an FDA conversation underway is squarely inside where capital is flowing; a US$66 million round is also roughly half the current median disclosed biotech round of about US$85 million, which reads as a targeted trial financing rather than a full re-capitalization.
Key Signal
"IBM continues to be a disabling, progressive disease with no approved treatment."
Namita Goyal, MD, Chief of the Neuromuscular Division, University of California, Irvine School of Medicine, and principal investigator of the MUSCLE study, in Abcuro's announcement
Regional Relevance
For the United States, this is a test of how far the FDA will let a sponsor go after a failed pivotal trial. Ulviprubart missed both its primary and its key secondary endpoints in a 272-patient study, and Abcuro is proposing to run a fresh registrational trial in the subgroup where a pre-specified analysis looked better. Regulators have grown more receptive to enrichment strategies in rare disease, where trial populations are small and no alternative exists, but the agency has also drawn hard lines on subgroup-driven filings. If Abcuro's design clears, it becomes a reference point for other rare-disease sponsors sitting on failed trials with an encouraging slice of data. For roughly 40,000 Americans with IBM by the company's estimate, the practical consequence is a wait: topline data are not expected until the second half of 2028.
For Massachusetts, the round keeps a Newton company and its clinical operations funded through a period when many biotechs in the state have cut staff or wound down after missed endpoints. Mass General Brigham Ventures, the venture arm of the state's largest hospital system, is again in the syndicate, which ties the local academic-medical complex to the outcome. The company's payroll and trial spending stay in the Boston cluster for at least two more years.
Internationally, the syndicate is unusually broad for a round this size. abrdn is Scottish, Pontifax is Israeli, Eurofarma Ventures is the venture arm of the Brazilian pharmaceutical group Eurofarma, and Kaitai Capital invests across Asia. Sanofi Ventures, the French drugmaker's corporate fund, has been in since the Series A era, which gives a large pharmaceutical company a long-standing window into the asset. Abcuro also counts European and Japanese patients in its prevalence estimate, so any eventual filing would likely extend beyond the U.S.
The Other Side
Can a drug that missed both its primary and key secondary endpoints be rescued by a subgroup? This is the central question, and the honest answer is that it depends on details not yet public. The favorable points are real: the subgroup was pre-specified rather than mined after the fact, Abcuro is proposing a fresh prospective trial in that population rather than trying to file on the existing data, safety was clean with falls as the most common adverse event at rates similar to placebo, no ulviprubart patient discontinued for a side effect, and nearly all completers rolled into the open-label extension. The uncomfortable point is the dose-response. In the overall population the low dose slowed decline by 29% and the high dose by 12.5%, the reverse of what a dose-dependent drug effect would predict, while in the less severe subgroup both doses converged at 50%. A pattern that inverts at one dose level and converges at another is consistent with a genuine effect obscured by noise, and it is equally consistent with noise. Independent analysis published by the patient organization Cure IBM raised a further complication that applies to the next trial too: the field has not settled how much slowing of progression is clinically meaningful in IBM, so even a statistically clean result could face debate about whether it matters to patients.
Is US$66 million enough, and what does an insider-led round signal? Abcuro raised US$200 million eighteen months ago to fund one registrational trial plus a BLA filing and launch preparation. This round is a third of that, for a trial starting in Q4 2026 and reading out in 2H 2028. The arithmetic implies either a leaner study design than MUSCLE or another raise before topline. The round is led by an existing investor with a single new participant, and BlackRock, which was named in the Series C syndicate, does not appear in the Series D list. Neither the valuation nor the structure was disclosed, so whether existing holders were marked down is unknown, and an insider round after a failed pivotal is a structure where that question is normally worth asking. Nothing improper is suggested by any of this; syndicates change for many reasons and existing investors leading a follow-on is common in rare disease. But the absence of a new lead outside the existing cap table is a data point about how the wider market priced the MUSCLE result.
Whose estimate of the patient population should a reader trust? Abcuro puts diagnosed U.S. patients at roughly 40,000 and prevalence across major European countries and Japan at roughly 35,000, with less severe disease accounting for nearly half. Fierce Biotech and pharmaphorum, covering the same company earlier, described about 50,000 patients across the U.S. and Europe combined, and pharmaphorum cited a Muscular Dystrophy Association figure of about 20,000 in the U.S. Abcuro's own release says its number is built from published epidemiology, the ICD-10 code and an estimate for undiagnosed and misdiagnosed patients — a methodology that is reasonable and also expansive. If the addressable population is half of the smaller figure rather than half of the larger one, a rare-disease launch economics case that already depends on premium pricing gets tighter, and the incentive to price aggressively rises. That cost lands on payers and, through cost-sharing, on patients who currently have nothing else.
